Shots:

• The company reported encouraging initial data from an ongoing P-I/II/III trial of its casirivimab + imdevimab (8-000/2-400mg) in hospitalized COVID-19 patients requiring low-flow oxygen. The results passed the futility analysis as seronegative patients treated with the Ab cocktail had a lower risk of death or receiving mechanical ventilation
• In seronegative patients- the cocktail reduced the time-weighted average daily viral load through day 7 by -0.54 log10 copies/mL & through day 11 by -0.63 log10 copies/mL- at day 5- the relative reduction vs PBO was -1.1 log10 copies/mL
• Both the Ab cocktail doses were well-tolerated. The Ab cocktail is designed to block the infectivity of SARS-CoV-2

 ­ Ref: PRNewswire | Image: Knowledge Ecology International